GlassScriptPhysician profile
Fernando Urrutia
NPI 1952336299
$5,982.00
in general payments reported to CMS, 2019-2025
27 companies · $1,411 in 2025
The $1,411 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $215 · 2020: $62.77 · 2021: $557 · 2022: $1,209 · 2023: $1,480 · 2024: $1,047 · 2025: $1,411.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,921 · Education: $16.94.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,921.26 |
| Education | $16.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,040.72 | 2021-2025 | Rinvoq, Linzess, Viberzi |
| Takeda Pharmaceuticals U.S.A., INC. | $674.04 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $617.89 | 2019-2025 | Stelara, Tremfya |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $368.86 | 2019-2025 | Xifaxan, Trulance |
| Celgene Corporation | $343.92 | 2022-2023 | Zeposia |
| Celltrion USA INC. | $290.00 | 2023-2025 | Vegzelma, Yuflyma |
| Pharmacosmos Therapeutics INC. | $283.92 | 2023 | Monoferric |
| Genzyme Corporation | $274.58 | 2022-2025 | |
| Pfizer INC. | $245.58 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $137.60 | 2023-2025 | Dupixent |
| Lilly USA, LLC | $113.43 | 2024-2025 | Omvoh |
| Ferring Pharmaceuticals INC. | $110.32 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $109.44 | 2020-2024 | Dificid |
| Aimmune Therapeutics, INC. | $82.12 | 2024-2025 | Zenpep |
| Braintree Laboratories, INC. | $63.92 | 2019-2024 | Sutab, Suflave |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $30.23 | 2023-2024 | Voquezna |
| Sandoz INC. | $24.91 | 2024 | Hyrimoz |
| Alcresta Therapeutics, INC. | $24.48 | 2023 | Relizorb |
| Csl Behring | $21.05 | 2025 | Kcentra |
| Redhill Biopharma INC. | $18.39 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.23 | 2023 | Cyltezo |
| Shield Therapeutics INC | $18.08 | 2024 | |
| Qol Medical, LLC | $16.52 | 2022 | |
| Nestle Healthcare Nutrition INC. | $15.62 | 2022 | |
| Fresenius Kabi USA, LLC | $15.18 | 2023 | Idacio |
| Ardelyx, INC. | $13.81 | 2022 | |
| Romark Laboratories, Lc | $9.16 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fernando Urrutia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.